CARA
Cara Therapeutics, Inc.
1.11
USD
This page is just a preview of the data found in TrendSpider’s full version
Cara Therapeutics, Inc. stock is down -10.48% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 December’s closed higher than November. 0% of analysts rate it a buy.
Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)
